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Gonadotropin therapy plays an integral role in ovarian stimulation for infertility treatments. Efforts have been
made over the last century to improve gonadotropin preparations. Undoubtedly, current gonadotropins have
better quality and safety profiles as well as clinical efficacy than earlier ones. A major achievement has been
introducing recombinant technology in the manufacturing processes for follicle-stimulating hormone,
luteinizing hormone, and human chorionic gonadotropin. Recombinant gonadotropins are purer than urine-
derived gonadotropins, and incorporating vial filling by mass virtually eliminated batch-to-batch variations and
enabled accurate dosing. Recombinant and fill-by-mass technologies have been the driving forces for launching
of prefilled pen devices for more patient-friendly ovarian stimulation. The most recent developments include the
fixed combination of follitropin alfa + lutropin alfa, long-acting FSH gonadotropin, and a new family of prefilled
pen injector devices for administration of recombinant gonadotropins. The next step would be the production of
orally bioactive molecules with selective follicle-stimulating hormone and luteinizing hormone activity.
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& INTRODUCTION
Gonadotropin therapy plays an integral role in ovarian
stimulation for infertility treatments. It was introduced
almost one century ago, and the last 25 years have yielded
major advancements.
Treating anovulatory women through exogenous gona-
dotropin administration began in the 1960s. It then
expanded to ovulatory women undergoing treatment with
assisted reproduction technology (ART) in the 1980s (1-3).
In fact, the introduction of controlled ovarian stimulation
(COS) for multiple follicular development significantly
increased pregnancy rates in in vitro fertilization (IVF) (4).
Such stimulation protocols have been developed and
refined to maximize the beneficial effects of treatment while
minimizing complications and risks (5).
In this review, we first describe the gonadotropin
glycoprotein structure and actions. We then outline the
landmark research that generated the currently used
gonadotropins. Next, we critically discuss the quality,
safety, and clinical efficacy of commercially available
gonadotropins, and last, we present an overview of the
novel pharmaceutical preparations under investigation.
& GONADOTROPIN STRUCTURE AND FUNCTION
The three gonadotropins, follicle-stimulating hormone
(FSH), luteinizing hormone (LH) and human chorionic
gonadotropin (hCG), are glycoproteins composed of two
non–covalently linked protein subunits, the alpha and beta
subunits (6). The alpha subunit contains 92 amino acids
(AA) and is identical in FSH, LH, and hCG. In contrast, the
beta subunits are distinct and confer unique receptor
specificity as well as differential biological properties (7).
Its biological activity is provided by the attachment of
carbohydrate moieties, forming heterodimers (3). The extent
and pattern of glycosylation conveys the spectrum of
different charges, bioactivities and half-lives for each
glycoprotein (8). Glycoproteins have two basic types of
glycosylation patterns: O-linked glycosylation, which is
characterized by a carbohydrate N-acetylgalactosamine
(GalNAc) attached to the hydroxyl group of an amino acid,
serine or threonine, and N-linked glycosylation, which is
characterized by an N-acetyl glucosamine (GlcNAc)
attached to the amide group of asparagine (Asn) (9). The
oligosaccharides often terminate with sialic acid and/or
sulfonated b1–4-linked GalNAc (SO3-4GalNAc) (10,11).
Molecules with a large number of sulfonated Gal-NAcs
disappear faster from the circulation than less-sulfonated
isoforms due to their affinity for liver SO3-4GalNAc
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receptors (10,12). On the other hand, more sialic acids
enhance the half-life (10,13).
Follicle-stimulating hormone
The FSH beta subunit is composed of 111 AAs with four
N-linked glycosylation sites, two on the alpha subunit
(Asn52 and Asn78) and two on the beta subunit (Asn7 and
Asn24) (9,14). Thus, each subunit is attached to two
carbohydrate moieties with variable compositions that, in
turn, create different isoforms with different plasma half-
lives (ranging from 3 to 4 hours) and bioactivities (Figure 1)
(3,9). Sialic acid residues are much more common in FSH
than sulfonated residues (13). Increased sialylation enhances
FSH metabolic stability by decreasing both glomerular
filtration and clearance by liver sialoglycoprotein receptors,
which is the major site for gonadotropin clearance (15,16).
FSH stimulates the recruitment and growth of early antral
follicles (2-5 mm in diameter) by binding to the G protein-
coupled receptors expressed exclusively on granulosa
cells (GCs) (17,18). An adenylate cyclase-mediated signal
is activated, followed by the expression of multiple mRNAs
that encode proteins responsible for cell proliferation,
differentiation, and function. FSH stimulates GC prolifera-
tion and growth (mitogenic action) and induces aromatase
activity via P450 activation (19). Concomitantly, the number
of FSH receptors increases as GCs respond to FSH. The
regulation of GC FSH receptor activity involves not only a
direct cAMP-mediated FSH influence on its own receptor
gene but also estrogen and other inhibitory agents, includ-
ing epidermal growth factor, fibroblast growth factor, and
GnRH-like protein. Inhibin and activin, which are also
produced by granulosa cells in response to FSH, have
autocrine activity and stimulate FSH receptor production,
thus enhancing FSH action (19,20).
Luteinizing hormone
The LH beta subunit is comprised of 121 AAs, which is a
difference that confers specific biologic activity and facil-
itates its interaction with the LH receptor (3). LH b-subunits
contain a single site with N-linked glycosylation (Asn 30)
and fewer sialic acid residues (only 1 or 2); as such, LH has a
short half-life of only 20 to 30 minutes (Figure 1) (15).
LH plays a key role in promoting steroidogenesis and
developing the leading follicle; it has different functions at
different stages of the cycle (19-22). During the early
follicular phase, LH stimulates androgen production by
theca cells. Cholesterol is converted into androgens (testos-
terone and androstenedione) through the transcription of
the cholesterol side-chain cleavage enzyme (P450scc),
P450c17, and 3b-hydroxysteroid dehydrogenase (3b-HSD)
genes (Figure 2). Androgens are then transferred to the GC
and transformed into estrogens via aromatization (21).
Finally, LH promotes final follicular maturation via its
direct effects on the GC in the late follicular phase (22).
Theca cells and GCs also secrete peptides, including insulin-
like growth factor (IGF), inhibin, and activin, which act as
both autocrine and paracrine factors and modulate LH-
mediated androgen production in the thecal compartment
as well as FSH-mediated aromatization in GCs (19,20,23).
Human chorionic gonadotropin
Although the beta subunit of hCG has an AA sequence
similar to LH, a notable difference is the presence of a long
carboxyterminal segment with 24 AAs containing four O-
linked oligosaccharide sites (Figure 1) (3,9). In addition,
hCG beta subunits contain two sites of N-linked glycosyla-
tion compared with a single LH site. Due to the higher
number of both glycosylation sites and sialic acid residues
(approximately 20) compared with LH, hCG exhibits a
markedly longer terminal half-life of 24 hours compared
with approximately 30 minutes for LH (15).
Due to their similar structure, hCG binds the same
receptor as LH. In gonadotropin therapy, hCG is used to
promote the final follicular maturation stages and progres-
sion of the immature oocyte at prophase I (the germinal
vesicle stage) through meiotic maturation to metaphase II
(3). The meiotic process requires approximately 36 hours to
complete; a few hours later, ovulation occurs. As such,
follicular aspiration upon oocyte retrieval is timed with hCG
administration in IVF. In addition, hCG can be used to
Figure 1 - Gonadotropin Molecules. The alpha and beta subunits are represented by red and blue strands, respectively, whereas the
carbohydrate chains are represented by light blue balls. A) Follicle-stimulating hormone. FSH is a glycoprotein composed of two
subunits, the alpha subunit (red) and the beta subunit (blue). There are four carbohydrate attachment sites, two in each subunit. B)
Luteinizing hormone. LH is a glycoprotein with two subunits, the alpha subunit (red), which is similar to FSH and hCG, with two
carbohydrate attachment sites, and the beta subunit (blue) with only one carbohydrate attachment site. C) Human chorionic
gonadotropin. hCG has structural attributes similar to LH. A notable exception is the presence of a long carboxy-terminal segment that
is O-glycosylated (O-linked CHO), conferring a longer half-life to hCG.
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maintain luteal function until placental steroidogenesis is
well established (19).
& MILESTONES IN GONADOTROPIN
DEVELOPMENT
Researchers began to develop gonadotropin preparations
in 1910, when experimental evidence suggested that the
pituitary has a role in regulating gonadal stems (2). Zondek,
in collaboration with Ascheim (1927), demonstrated that
blood and urine from pregnant women contained a gonad-
stimulating substance capable of inducing both follicular
maturation and ovarian stromal luteinization when injected
into immature mice. This substance was shown to be hCG,
which is produced in the placental tissue of the syncytio-
trophoblast (2,3,24). In vitro hCG production was then
possible through placental tissue culture, and commercial
hCG was first available in 1931 (2,3). Early observations
revealed that hCG administered alone in the follicular phase
failed to promote follicular development and ovulation,
thus indicating that hCG had no effect in the absence of FSH
(2,25). In contrast, a number of trials demonstrated that
gonadotropins extracted from the blood of pregnant mares
(PMSG) and from humans (post-mortem pituitary glands)
Figure 2 - Human Steroidogenesis. The starting point for steroid biosynthesis is the conversion of cholesterol in pregnenolone by
P450scc. One route for pregnenolone metabolism is the delta-5 pathway (red arrows) through CYP17 (P450c17). Pregnenolone
hydroxylation at the C17a position forms 17-hydroxypregnenolone, and subsequent removal of the acetyl group forms the androgen
precursor dehydroepiandrosterone (DHEA). An additional route for pregnenolone metabolism is the delta-4 pathway (purple arrows),
in which pregnenolone is converted to progesterone by 3b-HSD (an irreversible conversion). Progesterone is then converted to 17-
hydroxyprogesterone by CYP17. In humans, 17-hydroxyprogesterone cannot be further metabolized. Importantly, CYP17 is exclusively
located in thecal and interstitial cells in the ovary extrafollicular compartment, whereas CYP19 (aromatase), which converts androgens
to estrogens, is expressed exclusively in GCs, which are in the intrafollicular compartment. Androgen aromatization to estrogens is a
distinct activity that occurs in the granulosa layer, and it is induced by FSH via P450 aromatase (P450arom) gene activation.
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induced an ovarian response, but attempts to fully induce
ovulation produced inconsistent results (3,26). Human
pituitary extracts and PMSG were used in both Europe
and the United States until the early 1960s, despite findings
that such treatments produced neutralizing antibodies
(anti-hormones) that rendered the ovaries unresponsive to
repeated stimulation (2,3,27). By the mid-1980s, cases of
dementia and death due to iatrogenic Creutzfeldt-Jacob
disease (CJD) were identified in Australia, France, and the
United Kingdom and linked to human pituitary gonado-
tropin (hPG) use. As a consequence, hPG was banned from
the market approximately 20 years after its introduction
(2,3).
The recognition that animal gonadotropins induce anti-
hormone antibody production, which neutralized not only
the preparation administered but also endogenous gonado-
tropins, was the driving force behind gonadotropin extrac-
tion and purification from human sources. In the 1940s,
researchers began extracting gonadotropins from urine:
hCG in 1940 and human menopausal gonadotropin (hMG)
in 1949. A decade later, the first urinary forms of hCG and
hMG became commercially available (2,3). Further improve-
ments in the purification methods produced FSH-only
products in the 1980s and highly purified urinary FSH
(HP-hFSH) in 1993 (2,3). Advances in DNA technology
enabled the development of recombinant human FSH (rec-
hFSH), which became commercially available in 1995
(2,3,28). In 2000, recombinant human LH (rec-hLH) became
available and, with the launch of recombinant hCG (rec-
hCG) in 2001, the full recombinant gonadotropin portfolio
was launched (2,3). The most recent developments include
the introduction of the filled-by-mass (FbM) rec-hFSH
formulation in 2004, which improved batch-to-batch con-
sistency compared with products quantified by the standard
rat in vivo bioassay; long-acting FSH gonadotropin in 2010;
and novel pen injector devices to deliver precise recombi-
nant FSH, LH, and hCG doses in 2011 (29-35) (Figure 3).
& PREPARATIONS CURRENTLY AVAILABLE FOR
CLINICAL USE
Human menopausal gonadotropin (menotropin)
Menotropin is extracted from the urine of postmenopau-
sal women (2). Early preparations contained varying levels
of FSH, LH, and hCG in only 5% pure forms (3). The
purification techniques were improved, resulting in FSH
and LH with activities standardized at 75 IU for each type
of gonadotropin, as measured using a standard in vivo
bioassays (Steelman–Pohley assay). hMG preparations have
both FSH and LH activity, but the latter is primarily derived
from the hCG component in postmenopausal urine, which
is concentrated during purification (2,36,37). Occasionally,
hCG is added to induce a desired level of LH-like biological
activity (2). In 1999, purified hMG gonadotropins were
introduced, which facilitated its subcutaneous (SC) admin-
istration (3,29). Currently, both conventional hMG and
highly purified hMG (HP-hMG) are commercially available
at an FSH:LH ratio of 151 (29).
Urinary FSH (urofollitropin)
Urinary FSH preparations are produced by removing
LH with polyclonal antibodies. The production process is
Figure 3 - Milestones in the Development of Gonadotropin Preparations. FSH was originally derived from animal (pregnant mare
serum) or human (post-mortem pituitary glands) sources, but these preparations were abandoned due to safety concerns.
Gonadotropins were first extracted from urine in the 1940s; human chorionic gonadotropin (hCG) in 1940; and then human
menopausal gonadotropin (hMG) in 1949. Over a decade later, the first urinary forms of hCG and hMG became commercially available.
Further improvements in purification methods yielded follicle-stimulating hormone (FSH)-only products in the 1980s and the
subsequent development of highly purified FSH (HP-hFSH), which became available 10 years later, in 1993, and allows for subcutaneous
injection. In the 1970s and 1980s, advances in DNA technology enabled the development of recombinant human FSH (rec-hFSH), which
became commercially available in 1995. In 2000, recombinant human luteinizing hormone (rec-hLH) became available, and with the
launch of recombinant human hCG (rec-hCG) in 2001, the full recombinant gonadotropin portfolio was available. The most recent
developments include the filled-by-mass (FbM) follitropin alfa formulation, the fixed combination of follitropin alfa + lutropin alfa,
long-acting FSH gonadotropin, and a new family of prefilled pen injector devices.
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passive because LH is separated from the bulk material,
and FSH, together with certain other urinary proteins, is
collected and lyophilized. Though they were biologically
more pure, early preparations still contained high levels of
other urinary proteins (38). Further technological advances
facilitated the use of highly specific monoclonal antibodies
to extract FSH and produce highly purified FSH (HP-hFSH).
The latter has been commercially available since 1993 and
contains ,0.1 IU of LH and ,5% of unidentified urinary
proteins. The specific activity of FSH is approximately
10,000 IU/mg protein, whereas that of the earlier urinary
hMG preparations was 100–150 IU/mg protein (Table 1).
Similar to HP-hMG, the enhanced purity of HP-hFSH
enabled SC delivery (3). SC gonadotropin administration
represented an important advance for patients. Consistently
better tolerability (decreased pain at the injection site) was
reported for SC injections compared with the intramuscular
route (39,40). Moreover, SC administration allows self-
administration, which is more convenient and less time
consuming because patients require fewer visits to the clinic
or hospital for injections (39,40).
Recombinant FSH
Recombinant technology has met the need for a more
reliable FSH source. Under appropriate conditions, the
genes that code for the human FSH alpha and beta subunits
are incorporated into nuclear DNA of a host cell via a
plasmid vector using spliced DNA strings containing the
FSH gene and bacterial DNA segments (2,3,41). Early
recombinant technology used Escherichia coli. However,
due to the complex human gonadotropin structure and
the need for post-translational glycosylation, which defines
the degradation time and bioactivity, all recombinant
gonadotropins are now produced using the Chinese
hamster ovary (CHO) cell line. These cells are genetically
stable, fully characterized, and easily transfected with
foreign DNA. Furthermore, the cells can be grown in cell
cultures on a large scale, and can produce adequate levels of
biologically active recombinant gonadotropins (2,41).
Two types of recombinant FSH (rec-hFSH), the alfa and
beta follitropins, are available for clinical use (2). In
follitropin alfa, two separate vectors, one for each subunit,
are used to construct the master cell bank for an FSH-
producing cell line. Follitropin beta uses a single vector that
contains the coding sequences for both subunit genes
(41,42). The subsequent production steps are similar for
both preparations. Nevertheless, in addition to a series of
anion and cation exchange chromatography steps, hydro-
phobic chromatography and size exclusion chromatography
used to produce follitropin beta, an immunoaffinity step
with a specific monoclonal antibody similar to the antibody
used for HP-hFSH production is used for follitropin alfa
(Figure 4) (2,41). Due to the slight differences in their
production and purification procedures, the preparations
are not identical, with variations in posttranslational
glycosylation that yield different sialic acid residue compo-
sitions and different isoelectric coefficients (3,43,44). While
follitropins alfa and beta are similar to the native FSH
isoforms in the blood around mid-cycle (more basic
isoforms), they differ slightly in charge heterogeneity, as
follitropin alfa has slightly more acidic glycoforms than
follitropin beta (43,45). The preparations include equivalent
immunopotency, in vitro biopotency, and internal carbohy-
drate complexity (43,46). The initial and terminal half-lives
after the administration of 150 IU recombinant FSH are 2
and 17 hours, respectively. Given their intrinsically similar
structures, clinical efficacy is expected to be the same
(3,43,46).
Long-acting recombinant FSH (corifollitropin alfa)
Due to the relatively short half-life of FSH, daily FSH
injections are used to prevent serum FSH levels from
decreasing below the threshold that causes follicular growth
arrest (47). After each injection, the peak serum FSH levels
are reached within 10–12 hours; the FSH levels then decline
until the next injection. Steady state levels are reached only
after treatment for 3–5 days; thus, dose adjustments before
day 5 of stimulation are not advised (48).
Recently, a novel long-acting gonadotropin molecule was
developed by combining rec-hFSH with the hCG C-terminal
peptide (CTP) using site-directed mutagenesis and gene
transfer techniques (48). Its longer half-life is due to the hCG
CTP, which includes four additional O-linked carbohydrate
side chains, each with two terminal sialic acid residues
(15,49,50). The new molecule was created using a chimeric
gene containing the sequence that encodes CTP fused to the
translated human FSH beta subunit sequence. The chimera
was then transfected with the common glycoprotein alpha
subunit and expressed in CHO cells. The CTP sequence
does not significantly affect assembly or secretion of the
intact dimer by stable cell lines. The chimeric recombinant
molecule has similar in vitro receptor binding and steroido-
genic activity compared with wild-type FSH but exhibits
significant enhancement of its in vivo activity and plasma
half-life (48,51).
Corifollitropin alfa, initially produced in 2010, exclusively
interacts with FSH receptors and has a plasma half-life of
65 hours (33,51). Clinical studies indicate that a single
Table 1 - Differences between gonadotropin formulations.
Purity (gonadotropin content)
Mean Specific Activity
(IU/mg protein) LH Activity (IU/vial) Injected Protein per 75 IU (mcg)
hMG ,5% ,100 75* ,750
HP-hMG ,70% 2,000-2,500 75* ,33
rec-hFSH
Follitropin beta .99% 7,000-10,000 0 8.1
Follitropin alfa .99% 13,645 0 6.1
Lutropin alfa (rec-hLH) .99% 22,000 75 3.7
rec-hFSH: recombinant human follicle-stimulating hormone; hMG: human menopausal gonadotropin; HP-hMG: highly purified human menopausal
gonadotropin.
*Primarily derived from the hCG component, which is preferentially concentrated during the purification process and may be added to generate the
desired level of LH-like biological activity (approximately 8 IU of hCG per vial of 75 IU).
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injection of corifollitropin alfa can replace the first seven
daily standard gonadotropin injections and that stimulation
could be continued with daily FSH injections until the final
oocyte maturation had been reached (52).
Gonadotropin preparations with LH activity
Currently, three groups of commercially available gona-
dotropin preparations contain LH activity: (i) urinary hMG,
in which LH activity depends on hCG rather than pure
LH glycoprotein; (ii) pure LH glycoprotein produced by
recombinant technology (lutropin alfa), and (iii) a combina-
tion of pure FSH and LH glycoproteins in a fixed ratio of
251, which is also manufactured through recombinant
technology (Table 1) (3).
While hMG has been used for ovarian stimulation since
1960, lutropin alfa was introduced in 2000 for women with
gonadotropin insufficiency. It is intended to be administered
through subcutaneous daily injections. Recently, a new
prefilled pen device was introduced for rec-hLH administra-
tion (53). Currently, rec-hLH is used both to support follicular
development during COS in hypogonadotropic hypogona-
dal women and to offer LH supplementation to subsets of
women undergoing COS (2,54,55). Rec-hLH has three
major differences compared to hMG. First, it has higher
purity and specific activity due to the use of recombinant
technology. Second, it is associated with better dose
precision due to the vial/device filling method, which
virtually eliminates batch-to-batch variation (2,30,56).
Third, the LH activity is derived directly from pure LH
glycoprotein, unlike hMG, in which hCG is concentrated
during purification or added to achieve the desired level of
LH-like biological activity (2). LH and hCG differ in their
carbohydrate moiety compositions, which in turn, affect
bioactivity and half-life. In serum, LH activity is 30-fold
higher when hCG is used because it binds LH receptors
with greater affinity. Rec-hLH is eliminated with a terminal
half-life of 10-12 hours, in contrast to the 24-31 hours
required for hMG preparations with hCG-driven LH
activity (15,57-61).
A new combination of rec-hFSH and rec-hLH (follitropin
alfa + lutropin alfa) at a 251 ratio was launched in 2007. This
combination is advantageous for women who require LH
supplementation because a single injection, rather than two,
is used to deliver both preparations. The bioequivalence of
Figure 4 - Recombinant gonadotropin technology. Chinese hamster ovary cells are first grown in T-flasks, then subcultured in roller
bottles and allowed to expand for up to 36 days. Next, the cells are mixed with a microcarrier bead suspension and transferred to a
bioreactor vessel continuously perfused with a growth-promoting medium for an average of 34 days. The cell culture supernatant
medium containing ‘crude glycoprotein’ is collected from the bioreactor and stored at 48˚C until purification. The protein is purified by
chromatography followed by ultrafiltration. The final product is released after extensive quality control testing over 7 weeks.
Gonadotropins in assisted reproduction
Lea˜o RB and Esteves SC
CLINICS 2014;69(4):279-293
284
rec-hFSH and rec-hLH administered alone or in combina-
tion is similar (32,62).
Human chorionic gonadotropin
hCG administration is the gold standard for promoting
ovulation induction as a substitute for the mid-cycle LH
surge (63). Due to structural and biological similarities,
hCG and LH bind to and activate the same receptor (64).
However, the luteotropic activity of hCG is markedly
higher than that of LH due to its longer half-life and greater
receptor affinity (57,65). Currently, urinary hCG prepara-
tions are marketed in lyophilized vials with 5,000 or
10,000 IU for intramuscular use. In 2001, an hCG prepa-
ration (choriogonadotropin alfa) was launched using
recombinant technology. Recombinant hCG (rec-hCG) is
available in prefilled syringes containing 250 mcg of pure
hCG, which is equivalent to approximately 6,750 IU of
urinary hCG (3). Due to its higher purity, rec-hCG is better
tolerated and used subcutaneously, thus allowing patient
self-administration (66). Nevertheless, the clinical efficacy
of both urinary and recombinant preparations does not
seem to differ (67). In a Cochrane meta-analysis including
11 randomized controlled trials (RCTs) of IVF with 1,187
women, Youssef et al. compared rec-hCG vs. urinary
hCG for triggering final oocyte maturation. A significant
difference was not detected in the main outcome measure-
ments between the drugs: ongoing pregnancy/live birth
rate (6 RCTs: odds ratio [OR] = 1.04, 95% confidence
interval [CI]: 0.79 to 1.37; I2 = 0%), incidence of ovarian
hyperstimulation syndrome (OHSS) (3 RCTs: OR= 1.5, 95%
CI: 0.37 to 4.1; I2 = 0%) and the number of retrieved oocytes
(9 RCTs: Mean difference = -0.04, 95% CI: -0.69 to 0.62;
I2 = 18%) (67).
Table 2 summarizes the gonadotropin preparations
currently available for clinical use.
& QUALITY AND SAFETY PROFILES
Manufacturing urine-derived gonadotropins requires
high levels of human urine as a primary source. In the
1960s and 1970s, when the demand for gonadotropins was
low, the source material quality was controlled. However,
the widespread availability of infertility treatments has
rapidly increased demand since 1980. Unlike blood, human
urine is not subject to specific regulations regarding
collection. Because collected urine is pooled, the donor
source cannot be traced, and quality cannot be checked
throughout all manufacturing steps (38,68,69). However,
extraneous urinary proteins may account for more than 30%
of the protein levels in highly purified hMG products even
with sophisticated purification techniques (56,69). Certain
impurities have been identified as prion proteins, which
have been associated with transmissible spongiform ence-
phalopathy (TSE) diseases (70). Prion inactivation in urine-
derived material may also denature other proteins, includ-
ing FSH. In fact, several regulatory agencies limit urine-
derived products (38,68). In contrast, each product batch of
recombinant gonadotropin is routinely characterized and
controlled using physicochemical techniques. The techni-
ques include size exclusion high-performance liquid chro-
matography (SE-HPLC), which facilitates assessment of
both the integrity and the levels of glycoproteins, as well
as isoelectric focusing (IEF) and glycan mapping, which
are used to characterize the protein glycoforms in each
preparation (71,72). Due to the linear relationship between
recombinant gonadotropin mass and biological activity, a
new method was developed to calibrate each batch of
follitropin alfa, lutropin alfa, and choriogonadotropin.
Although the Steelman–Pohley assay is used to quantify
the protein levels in urinary preparations, which inherently
vary up to 20%, recombinant products are filled and
released based on protein mass (FbM) (30,73). FSH at
Table 2 - The most common gonadotropins available for clinical use.
Product Technology Brand name Manufacturer
HMG Urine derived Menogon; Repronex Ferring
HP-hMG Urine derived Menopur Ferring
Merional IBSA
HP-hFSH Urine derived Fostimon IBSA
Bravelle Ferring
U-hCG Urine derived Choragon Ferring
Brevactid Ferring
Choriomon, Gonasi HP IBSA
APL Wyeth-Ayerst
Biogonadyl Biomed-Lublin
Primogonyl Schering-Plough
Endocorion Win-Medicare
Corion Wyeth-Ayerst
Rec-hFSH
Follitropin beta Recombinant Puregon; Follistim Merck Sharp & Dohme
Follitropin alfa Recombinant GONAL-f MerckSerono
Long-acting FSH
Corifollitropin alfa Recombinant Elonva Merck Sharp & Dohme
Rec-hLH
Lutroprin alfa Recombinant Luveris MerckSerono
Rec-hFSH + rec-hLH 2:1
Follitropin + Lutropin alfa Recombinant Pergoveris MerckSerono
Rec-hCG Recombinant Ovidrel; Ovitrelle; Ovidrelle MerckSerono
HMG: human menopausal gonadotropin; HP-hMG: highly purified human menopausal gonadotropin; u-hCG: urinary human chorionic gonadotropin;
rec-hFSH: recombinant human follicle-stimulating hormone; rec-hLH: recombinant human luteinizing hormone; rec-hCG: recombinant human chorionic
gonadotropin.
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75 IU was assessed using the Steelman-Pohley method,
which corresponds to 5.0-5.5 mg of follitropin alfa, with a
dose variability of only 2% (3,30). This method ensures that
a precise dose is delivered, thus maximizing the beneficial
effects of gonadotropin therapy (3,29).
The pharmaceutical presentation of urinary gonadotro-
pins consists of a freeze-dried lyospheres containing either
75 IU of FSH/hMG or 5,000/10,000 IU of hCG. The lyoph-
ilized powder is then reconstituted using sterile water
before injection (29). Higher gonadotropin purity yields
higher specific activity, and therefore, less material is
injected for the desired effect. Through these characteristics,
highly purified urine-derived and recombinant gonadotro-
pins can be administered subcutaneously (56). Given the
high specific activity of recombinant gonadotropins, mini-
mal volumes are injected, and injection devices have been
developed to deliver the drug (40). The first injector was
an adapted insulin pen. Early studies showed that drug
delivery was more precise and better tolerated using the
pens than syringe injections. Due to unavoidable losses
during syringe filling and/or removing excess air, 18% of
the FSH amount is lost in conventional syringe applications
when compared with a ready-for-use solution in a pen
device (40). Recently, novel devices were specifically
developed for gonadotropin administration. The first gen-
eration was released in 2004 followed by a second
generation in 2011 (34,35). They are presented as ready-to-
use, compact, and disposable pens, FbM with a fixed drug
dose that can be administered in fractions over several days
(30,56). In an RCT including 100 women, the efficacy,
convenience, and local reactions after follitropin alfa
administration were compared following the use of either
the pen device or a conventional syringe. Outcomes,
including self-administration and patient satisfaction
(p,0.001), the overall incidence of local reactions (p= 0.04),
the overall pain score (p,0.001), and burning sensation at
the injection site (p=0.04), clearly favored the pen device
group (74). Later, in 2007, patients and their partners
received nurse-led training on three gonadotropin presenta-
tions: (i) powdered urofollitropin administered using con-
ventional needles and syringes, (ii) follitropin beta in a
premixed and prefilled cartridge with a reusable injection
device, and (iii) follitropin alfa in a disposable, premixed,
and prefilled injection device. One hundred twenty-three
participants attended the training and were asked to
complete a post-training questionnaire. More participants
expressed a preference for using pen injectors compared
with conventional syringes (84.6% vs. 5.7%; p,0.0001). Of
the 94 participants who preferred a particular device, more
preferred the follitropin alfa prefilled pen (68.1%) than
either the follitropin beta cartridge and pen (24.5%;
p,0.0001) or urofollitropin with a needle-free reconstitution
device and conventional syringe (7.4%; p,0.0001) (75). In
conclusion, recombinant technology, the FbM method, and
the use of pen devices for gonadotropin administration
represent important advancements that have made inferti-
lity treatments more patient friendly (40,74,76).
& CLINICAL EFFICACY OF GONADOTROPINS
The literature is rich in meta-analyses comparing efficacy
for different gonadotropin products (77-81). The most recent
studies are summarized in Table 3. Despite the hetero-
geneity of several of these meta-analyses pertaining the
different stimulation protocols and choice of fertilization
with standard in vitro fertilization or intracytoplasmatic
sperm injection (ICSI), the overall conclusion is that both
urinary gonadotropins, mainly hMGpreparations, and recom-
binant FSH have similar efficacy in terms of achieving a
pregnancy or live birth per treatment cycle. While some of
these studies were in favour of hMG preparations, albeit the
lower confidence limits were 1% or less, others reported no
differences in pregnancy outcomes between the two treat-
ments. Furthermore, no significant differences were noted for
spontaneous abortion, multiple pregnancy, cycle cancellation
and OHSS rates. Notably, these studies did not stratify
patients according to the need for LH supplementa-
tion during COS. This is a relevant aspect given the fact
rec-hFSH has solely FSH activity and recent evidence
indicates that a subset of women benefit from LH supple-
mentation during COS (55).
Several studies have also compared the potency of
different gonadotropin formulations (29,60,82,83). In an
RCT involving 629 women undergoing IVF/ICSI treatment
with pituitary down-regulation, Hompes et al. compared
HP-hMG and rec-hFSH. In their study, more oocytes were
retrieved from patients treated with rec-hFSH (7.8 and 10.6,
respectively; p,0.001), with no differences in pregnancy
rates (82). Similarly, in an RCT involving 280 women
undergoing IVF/ICSI with GnRH antagonists, Bosch et al.
obtained more oocytes from patients who received rec-
hFSH compared with those who received hMG (14.4¡8.1
vs. 11.3¡6.0, respectively; p,0.001). No significant differ-
ences were observed in the ongoing pregnancy rate per
initiated cycle (35.0 vs. 32.1%, respectively; RR= 1.09; 95%
CI: 0.78–1.51; risk difference [RD] = 2.9%) (60). Recently, in a
large RCT involving more than 700 patients in a single
blastocyst transfer IVF program, Devroey et al. confirmed
that rec-hFSH results in more oocytes than HP-HMG when
used at the same doses (10.6¡5.8 vs. 9.1¡5.2; p,0.001) (83).
We also compared different gonadotropin products in a
large observational study involving 865 women undergoing
IVF/ICSI with pituitary down-regulation, and found that
the total gonadotropin dose was significantly lower in
women who received rec-hFSH (2,268¡747 IU) compared
with hMG (2,685¡720 IU) or HP-hMG (2,903¡867 IU;
p,0.001). In our study, the live birth rates per cycle initiated
were the same in patients who received rec-hFSH (34.7%),
hMG (35.5%), or HP-HMG (40%). However, the total
gonadotropin dose required for a live birth was lower when
rec-hFSH was compared with hMG (52% reduction) and
HP-hMG (21% reduction) (29). The available data support
the notion that recombinant FSH is more potent than hMG
during COS (29,60,82,83).
The clinical efficacy of gonadotropins has also been
assessed with regard to the vial-filling method. In a meta-
analysis including four RCTs involving 1,055 women and
two case-control studies with 272 patients undergoing IVF,
the average rec-hFSH dose per patient was 230 IU lower
when the drug was FbM compared with the filled-by-
bioassay method (weighted mean difference [WMD]=
-230.3; 95% CI: -326 to -134.5; p,0.001). In addition, the
number of treatment days was reduced by 0.48 (WMD=
-0.48; 95% CI: -0.69 to -0.27, p,0.001), whereas the numbers
of oocytes retrieved (WMD=0.84; 95% CI: 0.18 to 1.51;
p,0.01) and embryos developed (WMD=0.88; 95% CI: 0.40
to 1.37; p,0.001) were higher in patients who received FbM
formulations. The clinical pregnancy (OR=1.3; 95% CI: 0.91
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to 1.82) and ovarian hyperstimulation syndrome (OHSS)
incidence rates (OR= 0.78; 95% CI: 0.45 to 1.36) were the
same for both formulations (84).
Similarly, long-acting and daily-use recombinant FSH
preparations have been compared. A meta-analysis of four
pharmaceutical industry-sponsored RCTs that included
2,377 participants evaluated the effectiveness, safety, and
tolerability of corifollitropin alfa compared with follitropin
beta in IVF/ICSI cycles with GnRH antagonists. The results
favored corifollitropin alfa with regard to the number
of oocytes retrieved (WMD=1.99; 95% CI: 1.02 to 2.97;
p,0.0001), the number of mature oocytes (WMD=1.92; 95%
CI: 1.25 to 2.59; p,0.001), and the number of embryos
formed (WMD=1.09; 95% CI: 0.68 to 1.49; p,0.0001). The
clinical pregnancy, live-birth, and miscarriage rates were
similar regardless of the drug used for COS. The median
duration of stimulation was 9 days in both groups,
indicating that two additional single daily rec-hFSH injec-
tions are required to complete the treatment regimen with
corifollitropin alfa. Notably, corifollitropin alfa resulted in
higher cycle cancellations due to an excessive response
(OR=5.67; 95% CI: 1.07 to 30.13; p= 0.04), but the OHSS
incidence was not significantly different between the groups
(OR=1.29; 95% CI: 0.78 to 2.26) (85). These results were
further corroborated by a recent Cochrane review of the
same studies (86). The main shortcoming of corifollitropin
alfa is that the dose cannot be adjusted during ovarian
stimulation, which is a particularly relevant limitation for
patients at risk of developing OHSS. From the data
available, corifollitropin alfa is likely efficacious and safe
for COS in normal responders, but it is not recommended
for women at risk of OHSS, such as women with polycystic
ovaries (85).
Luteinizing hormone supplementation during COS
The ‘‘LH window’’ concept outlined by Shoham in 2002
proposes that without a threshold level of serum LH,
estradiol production is insufficient for follicular develop-
ment, endometrial proliferation, and corpus luteum forma-
tion. However, exposing the developing follicle to excessive
LH would suppress GC proliferation, induce follicular
atresia of non-dominant follicles and premature luteiniza-
tion, and impair oocyte development (87). Under this
concept, optimal follicular development occurs when LH
is above a threshold of 1.1 and below a ceiling of 5.1 IU/L
(87,88). The validity of the LH threshold hypothesis has
been demonstrated in patients with hypogonadotropic
hypogonadism. These women do not achieve adequate
steroidogenesis unless LH is added to the stimulation
regimen (88).
Unlike pituitary insufficiency, most women undergoing
COS for IVF have adequate endogenous LH levels and thus
do not require LH supplementation (Table 4) (89-92).
Indeed, only 1% of LH receptors must be occupied to drive
adequate ovarian steroidogenesis (93,94). Nevertheless, the
ovarian response to FSH-only gonadotropins is suboptimal
in certain patient groups, including older women ($35 years
old) (55,95) and women with a diminished ovarian reserve
(54,81) or highly suppressed endogenous LH (96-100).
Further, a subset of normogonadotropic women have a
suboptimal response to FSH stimulation despite a normal
ovarian reserve (101-105). All these patients share a similar
trait, less sensitive ovaries, which can be explained by
several factors, including reduced paracrine ovarian activity
(106), LH receptor polymorphisms (105), reduced androgen
secretory capacity (107), fewer functional LH receptors
(108), and reduced LH bioactivity despite normal LH
immunoreactivity (109-110).
It has been hypothesized that these women would benefit
from preparations containing LH, which would act at the
follicular level. An increase in androgen production for
future aromatization into estrogens could restore the
follicular milieu and thus positively impact oocyte quality
(97,99,103,111,112). In fact, several studies have assessed the
utility of LH supplementation during COS (Table 4). A
recent meta-analysis by Hill et al., which included seven
RCTs and 902 older women undergoing COS for IVF,
demonstrated significantly higher embryo implantation
(OR=1.36; 95% CI: 1.05 to 1.78, I2 = 12%) and clinical
pregnancy rates (OR= 1.37; 95% CI: 1.03 to 1.83, I2 = 28%)
Table 3 - Meta-analyses comparing urinary and recombinant gonadotropins for controlled ovarian stimulation in in
vitro fertilization.
Authors, Year Gonadotropins No. RCT No. Patients Main Findings
Coomarasamy
et al., 2008
rec-hFSH; hMG 7 2,159 Higher clinical pregnancy (RR = 1.17, 95% CI: 1.03-1.34) and live birth rates
(RR = 1.18, 95% CI: 1.02-1.38; p= 0.03) with hMG. No significant differences in the
spontaneous abortion, multiple pregnancy, cycle cancellation, or OHSS rates.
Al Inany et al.,
2009
rec-hFSH; hMG; HP-hMG 6 2,371 Overall, no significant differences in the clinical, ongoing pregnancy, or live birth
rates. Higher ongoing pregnancy/live-birth rates with HP-hMG (OR = 1.31, 95% CI:
1.02-1.68; p=0.03) after grouping the treatment cycles by method, ICSI and IVF.
Jee et al., 2010 rec-hFSH; HP-hMG 5 2,299 No difference in ongoing pregnancy rate per initiated cycle (RR = 1.10; 95% CI:
0.96-1.26) or live birth rates per embryo transfer (RR = 1.14; 95% CI: 0.98-1.33).
Van Wely et al.,
2010
rec-hFSH; hFSH-P; HP-hFSH;
hMG; HP-hMG
28 7,339 Overall, no difference in live birth or OHSS rates.
Van Wely et al.,
2012
rec-hFSH; hMG; HP-hMG 12 3,197 Fewer clinical pregnancies (OR = 0.85; 95% CI: 0.74-0.99; I2 = 0%; p= 0.03) and live
births with rec-hFSH (OR = 0.84; 95% CI: 0.72-0.99; I2 = 0%; p= 0.04).
Gerli et al., 2013 rec-hFSH; hFSH-P; HP-hFSH 8 955 No difference in the clinical pregnancy (OR = 0.85, 95% CI: 0.68 to 1.07) or live
birth rates (OR = 0.84; 95% CI: 0.63-1.11).
RCT: randomized controlled trial.
rec-hFSH: recombinant human follicle-stimulating hormone; hMG: human menopausal gonadotropin; HP-hMG: highly purified human menopausal
gonadotropin; hFSH-P: purified urinary follicle-stimulating hormone; HP-hFSH: highly purified urinary follicle-stimulating hormone; COS: controlled
ovarian stimulation.
RR: relative risk; CI: confidence interval; OR: odds ratio;
IVF: in vitro fertilization; ICSI: intracytoplasmic sperm injection; OHSS: ovarian hyperstimulation syndrome.
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when recombinant LH was added to the stimulation
regimen (55). Along the same lines, Mochtar et al., while
specifically studying poor responders, demonstrated the
benefit of adding rec-hLH during COS. These authors
pooled three RCTs, which included 310 participants, and
showed higher ongoing pregnancy rates (OR= 1.85; 95% CI:
1.1 to 3.11) in patients treated with a combination of rec-
hFSH and rec-hLH compared with rec-hFSH alone (91). In
contrast, Fan et al. also studied poor responders by pooling
three RCTs and found no differences in ongoing pregnancy
rates with LH supplementation (OR=1.30; 95% CI: 0.80 to
2.11). Furthermore, a significant difference was not detected
for the number of oocytes retrieved, the total rec-hFSH dose,
the total stimulation duration and the cycle cancellation rate
between the study and control groups (113). Finally, in a
meta-analysis that included 7 RCTs and 603 patients,
Bosdou et al. showed conflicting results following LH
supplementation. Although the results were not statistically
significant in their study, the magnitude of the size effect
and width of the 95% CI for clinical pregnancy (RD= +6%;
95% CI: -0.3 to +13%; p = 0.06) suggested a potential clinical
benefit of LH supplementation. Despite the heterogeinity of
the studies included with regard to patient selection,
stimulation protocol, and dose of rec-hLH, the results from
a single RCT revealed significantly higher live birth rates
after IVF upon LH supplementation (RD= +19%; CI: +1 to
+36%) (54).
In summary, existing evidence suggests that LH supple-
mentation could benefit select patient subgroups, but the
results should still be interpreted with caution for several
reasons. First, the definition of a poor ovarian response was
not uniform among studies. Second, the ovarian stimulation
protocols differed in dosing, the LH supplementation onset,
and the duration of stimulation. Third, the number of
completed trials remains low. Finally, many questions have
not been fully answered, including how to identify patients
who would benefit from LH supplementation, how much
LH is necessary, when to begin LH supplementation, and
which type of LH activity is best, i.e., recombinant LH or
hCG derived (54,99,113).
Notably, an open-label RCT compared the clinical efficacy
of LH supplementation using either recombinant LH (a
combination of follitropin alfa + lutropin alfa at a fixed
ratio of 251) or hCG-driven LH activity (HP-hMG) in a small
group of women with pituitary insufficiency. Although the
proportion of patients who reached ovulation did not
differ between the groups (70% vs. 88%, respectively), the
pregnancy rate was significantly higher in the rec-hLH
group (55.6% vs. 23.3%; p = 0.01) (114). Similarly, in an IVF
RCT involving 106 women with a normal ovarian reserve
and low endogenous LH levels (,1.2 IU/L), a shorter
stimulation duration (10.9¡1.1 vs. 14.1¡1.6 days; p= 0.013)
and more retrieved oocytes (7.8¡1.1 vs. 4.1¡12; p= 0.002)
were observed in patients who received follitropin alfa +
lutropin alfa 2:1 compared with HMG. At the end of
stimulation, the estradiol level (1,987¡699 pg/mL vs.
2,056¡560 pg/mL), pregnancy rate per cycle (28.3% vs.
29.3%) and implantation rate (12.1% vs. 12.2%) did not differ
between the groups. However, a higher cancellation rate
due to an excessive response was observed in women
receiving follitropin + lutropin alfa (11.1% vs. 1.7%;
p = 0.042) (115). Finally, a large matched case-control study
involving 4,719 IVF patients showed that the probability of
a clinical pregnancy was higher in patients who used the
fixed combination of rec-hFSH and rec-hLH at a 251 ratio
(32%) when compared with patients who used hMG (26%;
p= 0.02) (116). Not surprisingly, these limited data suggest
that the fixed rec-hFSH plus rec-hLH combination is
superior to hMG. Unlike rec-hLH, LH activity in hMG is
derived from hCG, which has a markedly longer half-life
and greater binding affinity for LH/hCG receptors com-
pared with LH (57). Lower expression of the LH/hCG
receptor gene as well as the genes involved in cholesterol
and steroid biosynthesis has been observed in GCs from
patients treated with hMG when compared with FSH-
treated patients (58). Constant ligand exposure to hCG
during the follicular phase likely produces these effects. In
fact, LH receptor down-regulation for up to 48 h has been
reported in animal models after hCG administration (59),
but the clinical implications of these findings have not been
fully elucidated in humans (61).
& FUTURE PERSPECTIVES
Low molecular weight (LMW) gonadotropins are cur-
rently under investigation. These non-peptide molecules
have in vivo bioactivity when administered orally (117,118).
The first LMW peptides with bioactivity for FSH receptors
were described in 2002. In recent years, other compounds
have been identified, including biaryl diketopiperazines,
thienopyrimidines, dihydropyridines, and thiazolidinones.
In the meantime, peptides with agonist activity for LH have
also been identified (117,118). However, the clinical efficacy
of these compounds has not been determined. FSH and
LH receptors compose a subgroup of G protein-coupled
receptors with seven transmembrane domains and a large
N-terminal extracellular region, which is the predominant
site for hormone binding (117,119,120). Receptor activation
requires that the hormone binds the N-terminal region, thus
leading to intramolecular signal transduction from the
ligand-receptor complex to the transmembrane domains.
Current LMW gonadotropins are allosteric compounds that
presumably interact with the transmembrane domains
instead of the N-terminal region. As such, the signaling
pathways induced differ from those induced by the native,
orthosteric ligands. Recently, a newly developed LMW
agonist for the FSH (and LH) receptor has been shown to be
orally bioactive in animal studies (118,119). In the future,
gonadotropins could be taken orally and replace the injec-
table forms currently available (117,118).
& REVIEW CRITERIA
An extensive search of studies examining the use of
gonadotropins in assisted reproduction was performed using
ScienceDirect, Google Scholar, PubMed, and MEDLINE. The
overall strategy for identification and data extraction in the
study was based on the following key words: ‘‘gonadotro-
pins’’, ‘‘follicle-stimulating hormone’’, ‘‘luteinizing hormone’’,
‘‘human chorionic gonadotropin’’, ‘‘controlled ovarian stimu-
lation’’, and ‘‘assisted reproductive technology’’. Only articles
published in English were considered. The end date for the
searches was May 2013. Data that were solely published in
conferences or meeting proceedings, websites, or books were
not included. Websites and book-chapter citations provided
conceptual content only. Concerning the clinical efficacy of
gonadotropins, only meta-analytic studies published after
2005 were included.
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